Business Description
Biocept Inc
NAICS : 621511
SIC : 8731
ISIN : US09072V4023
Description
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.57 | |||||
| Equity-to-Asset | 0.01 | |||||
| Debt-to-Equity | 39.97 | |||||
| Debt-to-EBITDA | -0.4 | |||||
| Piotroski F-Score | 1/9 | |||||
| Beneish M-Score | -10.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17 | |||||
| 3-Year EBITDA Growth Rate | 46.5 | |||||
| 3-Year EPS without NRI Growth Rate | 45 | |||||
| 3-Year FCF Growth Rate | 58.3 | |||||
| 3-Year Book Growth Rate | -36.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.89 | |||||
| 9-Day RSI | 38.95 | |||||
| 14-Day RSI | 40.3 | |||||
| 6-1 Month Momentum % | -99.97 | |||||
| 12-1 Month Momentum % | -100 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.81 | |||||
| Quick Ratio | 1.7 | |||||
| Cash Ratio | 1.35 | |||||
| Days Inventory | 28.7 | |||||
| Days Sales Outstanding | 2003.03 | |||||
| Days Payable | 57.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -46.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -1055.02 | |||||
| Operating Margin % | -2445.28 | |||||
| Net Margin % | -2257.23 | |||||
| FCF Margin % | -1347.86 | |||||
| ROE % | -213.89 | |||||
| ROA % | -82.63 | |||||
| ROIC % | -156.96 | |||||
| ROC (Joel Greenblatt) % | -160.49 | |||||
| ROCE % | -99.37 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.16 | |||||
| EV-to-EBITDA | -0.17 | |||||
| EV-to-Revenue | 3.66 | |||||
| EV-to-Forward-Revenue | 0.97 | |||||
| EV-to-FCF | -0.27 | |||||
| Earnings Yield (Greenblatt) % | -625 | |||||
| FCF Yield % | 4.22 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers